Metabolite Tales Blog
DECEMBER 12, 2024
The paper gives a useful insight into the most commonly used in vitro MetID practices across 26 pharma companies, and crucially reveals how effective these systems are at predicting circulating human metabolites. Hypha’s clients range from small through to large pharma companies.
H1 Blog
JUNE 7, 2023
Clinical trial success is a key factor for pharma companies when designing and recruiting patients into trials. In a recent article in Clinical Leader , Randy Krauss, head and executive director of metrics, analytics, and performance, Merck & Co., There is a tendency to want to measure everything.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Connected Lab
APRIL 8, 2020
Companies such as Cyclica have developed software that matches the biophysical and biochemical properties of millions of molecules to the structures and properties of approximately 150,000 proteins to uncover molecules that are likely to bind to a target 2. A Tough Road: Cost To Develop One New Drug Is $2.6 Nature , vol.
The Pharma Data
JANUARY 4, 2021
Rothenberg did not provide any information as to what his next role may be – whether he will take over the helm of a pharma company or assume a role on one or more boards of directors. I have every confidence in her continued success in this new role,” Rothenberg said.
Metabolite Tales Blog
DECEMBER 19, 2023
Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group A Metabolite Bioanalysis Working Group comprised of experts from 14 different pharma companies have proposed recommendations around best practice in metabolite bioanalysis during drug development.
Drug Target Review
OCTOBER 1, 2024
Looking ahead, what exciting developments or advancements do you foresee in your field of STEM, and how do you envision your own research contributing to those future innovations?
The Pharma Data
DECEMBER 21, 2020
The FOCUS trial is Ultimovacs’ fourth Phase II clinical trial with UV1 and comes in addition to the collaboration Phase II trial announced in May 2020. “We To date, UV1 has been tested in four phase I clinical trials in a total of 82 patients and maintained a positive safety and tolerability profile as well as encouraging signals of efficacy.
Expert insights. Personalized for you.
52 
Let's personalize your content